Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Equity Research

 

Commissioned research by Vator Securities is offered to selected life science companies – “By Invitation Only”

 

Commissioned Research: AlzeCure Pharma

7 July 2020

AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity.

We update our rating to Outperform and raise the target price to SEK 16 per share, corresponding to an equity value of approximately SEK 600m non-diluted, derived from risk-adjusted DCF valuation of ACD856 and ACD440. 

Commissioned research: AlzeCure Pharma

24 October 2019

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case.

The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta.

Commissioned research: AlzeCure Pharma

9 May 2019

AlzeCure’s lead product asset, ACD855, started clinical development in late 2018 with the ambition to generate first clinical trials by early 2020.

However, early human exposure with the tablet product demonstrated that the concentration of the substance would require significantly longer dosing intervals than once daily, so the future development of the substance will now only be pursued with a formulation targeting ophthalmologic disorders.

Commissioned research: AlzeCure Pharma

15 January 2019

AlzeCure Pharma is a Swedish-based pharmaceutical company with potentially first-in-class proprietary and novel targeted small molecule (tablets) candidates for neurodegenerative diseases with a primary target on Alzheimer’s Disease (AD).

AlzeCure’s management team has extensive big pharma experience, and formed an integral part of AstraZeneca’s CNS department.